DrugRepV Browse Page

DrugRepV browse page allows user to take a glance of the particular antiviral agent.Fields in the webpage is hylerlinked ot various external repositories like DrugBank, PubChem, Clinicaltrials.gov,and PubMed.User can explore the biological, Clinical, Chemical, and Structural details of every repurposed drug candidate.By clicking on the table header arrows, user can sort entries in ascending or descending order.


Total number of Records for HIV multiple-cycle replication assay are 16

DrugRepV_ID	Antiviral Name	Drug type	Primary Indication	Secondary Indication	Strain	Pathways	Assay	Activity	Clinical Status	References
DrugRepV_6522	MK-1439	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Wild type		HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6523	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Wild type		HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6524	Etravirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Wild type		HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6525	Rilpivirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Wild type		HIV multiple-cycle replication assay	Decrease (95 %)	Approved	24379202
DrugRepV_6526	MK-1439	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	K103N		HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6527	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	K103N		HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6528	Etravirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	K103N		HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6529	Rilpivirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	K103N		HIV multiple-cycle replication assay	Decrease (95 %)	Approved	24379202
DrugRepV_6530	MK-1439	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y181C		HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6531	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y181C		HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6532	Etravirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y181C		HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6533	Rilpivirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y181C		HIV multiple-cycle replication assay	Decrease (95 %)	Approved	24379202
DrugRepV_6534	MK-1439	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	K103N/Y181C		HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6535	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	K103N/Y181C		HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6536	Etravirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	K103N/Y181C		HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6537	Rilpivirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	K103N/Y181C		HIV multiple-cycle replication assay	Decrease (95 %)	Approved	24379202